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Background: Epidermal growth factor receptor (EGFR) is a member of the ErbB family of
tyrosine kinase receptor proteins that plays important roles in tumour cell survival and
proliferation. EGFR has been reported to be overexpressed in up to 78% of triple-negative
breast cancer (TNBC) cases suggesting it as a potential therapeutic target. The clinical trials
of anti-EGFR agents in breast cancer showed low response rates. However, a subgroup of
patients demonstrated response to EGFR inhibitors highlighting the necessity to stratify
patients, who might beneﬁt from effective combination therapy that could include anti
EGFR-agents. Population variability in EGFR expression warrants systematic evaluation in
speciﬁc populations.
Purpose: To study EGFR alterations and expressions in a multi ethnic Malaysian TNBC
patient cohort to determine the possibility of using anti-EGFR combinatorial therapy for this
population.
Patients and methods: In this study, we evaluated 58 cases of Malaysian TNBC patient
samples for EGFR gene copy number alteration and EGFR protein overexpression using
ﬂuorescence in-situ hybridization (FISH) and immunohistochemistry (IHC) methods,
respectively.
Results: EGFR protein overexpression was observed in about 30% while 15.5% displayed
high EGFR copy number including 5.17% gene ampliﬁcation and over 10% high polysomy.
There is a positive correlation between EGFR protein overexpression and gene copy number
and over expression of EGFR is observed in ten out of the 48 low copy number cases
(20.9%) without gene ampliﬁcation.
Conclusion: This study provides the ﬁrst glimpse of EGFR alterations and expressions in a
multi ethnic Malaysian TNBC patient cohort emphasising the need for the nationwide large
scale EGFR expression evaluation in Malaysia.
Keywords: FISH, ﬂuorescence in situ hybridization, IHC, immunohistochemistry, TNBC
biomarker, metastatic breast cancer
Introduction
Human breast cancers represent a heterogeneous group of tumors and can be
classiﬁed into different molecular subtypes based on histology, cellular origin,
mutations, metastatic potential, disease progression, therapeutic response and clin-
ical outcome.1 While signiﬁcant progress has been made for the treatment and
patient outcome of breast cancers, the treatment of triple-negative breast cancer
(TNBC) still remains a challenge due to its aggressive characteristics and limited
treatment options. TNBC is a group of breast tumors characterized by the absence
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of expression of estrogen receptors (ER), progesterone
receptors and human epidermal growth factor receptor 2
(HER2) and lacks the beneﬁt of speciﬁc therapy that
targets these proteins.2 This subtype of invasive breast
cancer carries a poor disease-free survival and associated
with poor clinical outcomes accounting overall for about
17% of all breast cancers.3,4 Among patients diagnosed
with resectable (stages I–III) TNBC who completed tri-
modality therapy (surgery ± radiotherapy + adjuvant or
neoadjuvant chemotherapy), as many as 50% of patients
experience disease recurrence and on an average 37% die
in the ﬁrst 5 years following surgery.5,6 When comparing
the TNBC of the Asian with the western population the
onset age is much lower at 40–50 among Asians compared
to western population (average age of occurrence 60–70).
The overall survival remains poor due to the common
occurrence of early relapse and predominant localization
of distal metastases in visceral organs. Currently, no spe-
ciﬁc targeted therapy approach is available for TNBC
outside clinical trials warranting novel targeting therapy
discovery.5,7
The commonly used systematic therapeutic options for
TNBC are limited to conventional cytotoxic chemotherapy,
whereas non-TNBC such as hormone receptor-positive, or
HER2-positive breast cancer beneﬁt from anti-hormonal or
HER2-targeted therapy. Current treatment strategies for
patients with TNBC include targeting angiogenesis through
vascular endothelial growth factor and proliferation signal-
ing focusing on agents for DNA repair, either directly
through (ADP-ribose) polymerase inhibitors or indirectly
through DNA-binding or DNA-damage potentiation.8
There are many ongoing TNBC trails for combination ther-
apy that include anti-EGFR agents due to its central role in
TNBC oncogenesis, metastasis and treatment outcome.
Moreover, anti-EGFR agents (geﬁtinib) inhibit phosphory-
lation in an in vitro setting on TNBC cell lines (BT20,
HCC1937 and MDA-MB-231) resulting in cell cycle arrest
indicating the possibility of using recently developed anti-
EGFR agents in TNBC treatment.9
The EGFR gene is located on chromosome 7p11.2,
which belongs to the ErbB family of receptor tyrosine
kinases that includes a ligand-binding extracellular
domain, transmembrane domain, and a cytoplasmic cata-
lytic kinase domain. The kinase was implicated in various
cancers owing to their signaling function in Ras-MEK-
ERK, PI3K-AKT-mTOR and Src-STAT3 pathways.10,11
The EGFR pathway contains well-established oncogenes
including EGFR, KRAS, BRAF and PIK3CA genes that
modulate gene activations in solid tumors including lung,
colorectal cancer (CRC) and pancreatic ductal
adenocarcinoma.12–15 The EGFR and EGFR-like peptides
are often over-expressed in human carcinomas, and in vivo
and in vitro studies have shown these proteins induce cell
transformation.16 Moreover, anti-EGFR therapies corre-
lated with longer survival of patients with colon carci-
noma, non-small cell lung cancer (NSCLC) and
squamous-cell of head and neck carcinoma.17
Several clinical studies analyzing EGFR protein
expression in various populations showed a wide variety
of results ranging from 13% positive EGFR expression
detected through immunohistochemistry (IHC) in Korea
and Italy to a very high positive expression of 76% in
Switzerland and 72% in France.18–21 The EGFR autocrine
pathway contributes to a number of processes pivotal in
breast cancer development and progression, including cell
proliferation and migration.22 Again gene ampliﬁcation
analyses from various countries showed a very high varia-
tion between 2% in German population to about 24% in
Switzerland. Atypical EGFR activation in tumor cells can
result from increased transcriptional expression, mutation
and/or gene ampliﬁcation.20 The increased EGFR protein
and transcript levels correlate with poor prognosis in var-
ious epithelial cancers, such as CRC, NSCLC and endo-
metrial cancer.23–25 In TNBC, EGFR expression is also
associated with poor clinical outcome and aggressive
metastasis in western population.19 It is therefore essential
to proﬁle for EGFR expression and variations in speciﬁc
population to ascertain the possibilities of using EGFR as
an independent prognosticator and anti-EGFR therapies.
Although the EFGR expression and gene alterations
are extensively studied in the western population, the
EGFR status in Malaysian TNBC cohort is completely
lacking. Here, we report the EGFR copy number alteration
and protein overexpression studied using ﬂuorescence in
situ hybridization (FISH) and IHC, respectively, in the
representative Malaysian TNBC cohort to review the pos-
sibility of stratifying patients using EGFR status and using
anti-EGFR therapy (Table 1).
Materials and methods
Patients and tissue samples
Fifty-eight formalin-ﬁxed parafﬁn-embedded (FFPE) satis-
factory tissues of patients with TNBC from 2005 to 2013
were obtained from Universiti Kebangsaan Malaysia
Medical Centre (UKMMC). The cases included in this
Zakaria et al Dovepress
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study are the ones that are classiﬁed as invasive ductal
TNBC based on the expression of standard biomarkers
(ER, progesterone and HER-2), immunohistochemical
data and those cases with complete clinical data.
Immunohistochemistry (IHC) analysis
Tissue sections with 4 µm thickness were cut from the
FFPE blocks, dried, deparafﬁnized and rehydrated using
standard operating procedures. The EGFR expression was
detected using monoclonal mouse anti-human EGFR,
wild-type (DAK-H1-WT) (Dako, Santa Clara, CA, USA)
antibody and EnVision™ FLEX+ High pH kit (Dako).
EGFR antibody was applied to a representative section
of the TNBC cases as manufacturer’s protocols, with
Proteinase K proteolytic epitope retrieval for 5 mins, fol-
lowed by incubation with the primary EGFR antibody at
room temperature for 30 mins. DakoCytomation Mouse
IgG1 (Dako) was used as negative control and colon
cancer was used as positive control. Both positive and
negative controls were run simultaneously with the test
samples. The slides were stained lightly with hematoxylin
prior to scanning and viewing.
EGFR expression was scored by pathologist as follow-
ing: 0, no staining or weak membranous staining in <10% of
the tumor cells; 1+, weak membranous staining in ≥10% of
the tumor cells; 2+, moderate membranous staining in ≥10%
of the tumor cells; 3+, strong membranous staining in ≥10%
of the tumor cells. Complete and incomplete membranous
staining were both accepted and a score of 2+ onwards was
considered to be EGFR overexpression (Table 2).
FISH assay for the detection of EGFR
gene alterations
FISH detection of EGFR gene alteration was performed
by hybridizing slides with ﬂuorescent-labeled dual-
colored probes, XL EGFR amp (MetaSystem,
Altlussheim, Germany) according to the manufacturer’s
instructions. The probe mixture consists of an orange
labeled probe which hybridizes to the EGFR locus at
7p11 and a green labeled probe which hybridizes to the
7cen region. The ﬂuorescence hybridization signal was
observed using ﬂuorescence microscope and analyzed
using CytoVision (Leica Biosystems, Nussloch,
Germany) software.
For each sample, 50 non-overlapping tumor cells
were evaluated. EGFR gene copy number was classiﬁed
into normal disomy (≤2 copies in >90% of cells); low
trisomy (≤2 copies in ≥ of 40% of cells, three copies in
10–40% of cells and ≥4 copies in <10% of cells); high
trisomy (≤2 copies in ≥40% of cells, 3 copies in ≥40%
of cells and ≥4 copies in <10% of cells); low polysomy
(≥4 copies in 10–40% of cells); high polysomy (≥4
copies in ≥40% of cells) and EGFR gene ampliﬁcation
(presence of high EGFR gene clusters and a ratio of the
EGFR gene to chromosome 7 of ≥2 or >15 copies of
EGFR per cell in ≥10% of cells).26 The cases were then
classiﬁed into two major groups which were low EGFR
copy number (disomy, low trisomy, high trisomy and
low polysomy) and high EGFR copy number (high
polysomy and gene ampliﬁcation).
Statistical analysis
Statistical analysis was carried out using Statistical
Package for Social Sciences (SPSS) software, version 10
(SPSS, Chicago, IL, USA). The Chi-square test was used
to determine the relationship between EGFR gene altera-
tions and EGFR protein expression. The result was con-
sidered to be statistically signiﬁcant at a P<0.05.
Table 1 Summary of patient samples analyzed in the study
Numbers Percentage
Age range of patients 26–89
Sex
Female 58 100
Male 0 0
Ethnicity
Malay 35 60.4
Chinese 14 24.2
Indian 6 10.4
Foreigner 3 5.2
Grade distribution
Grade1 4 6.9
Grade 2 19 32.7
Grade 3 35 60.4
Lymph node
Positive 18 31.1
Negative 17 29.3
Nil 23 39.6
Tumor size (cm) 1.5x1.5×1.0–15.0×9.0
T stage
T1 9 15.5
T2 37 63.8
T3 11 18.9
T4 1 1.7
Dovepress Zakaria et al
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Results
EGFR copy number alteration
In this study, FISH results were divided into low gene copy
number and high gene copy number. Of 58 TNBC cases,
gene ampliﬁcation was shown in three (5.2%) cases while
high polysomy in six (10.3%) cases. The 49 remaining cases
showing disomy were detected in six cases (10.3%), low
trisomy in 24 cases (41.4%), high trisomy in 14 cases
(24.1%) and low polysomy in ﬁve cases (8.6%). The percen-
tage of cells with EGFR gene ampliﬁcation was evaluated in
50 non-overlapping cells showing abnormal signal patterns
in ≥10% cells (Tables 2 and 3). Representative cases of low
copy number and high copy number of EGFR gene are
shown in Figure 1.
EGFR protein overexpression evaluation
IHC study on 58 cases of TNBC showed 17 (29.3%) cases
with high immunoreactivity (overexpression) with score
value of 2+ and more. Of these 17 cases, 10 cases (17.2%)
were scored as 2+ and 7 cases (12.1%) were scored as 3+
(annotation of the scoring described in Table 4). The
remaining cases were scored as 0 (44.8%) and 1+
(25.9%). The classiﬁcation for IHC results (0, 1+, 2+ and
3+) were based on the morphological protein expression
observed after staining (Figure 2). For many decades,
invasive breast carcinomas were only classiﬁed according
to histological type, grade and expression of hormone
receptors but separating the EGFR overexpressing subset
in TNBC will allow us to explore the possibility of using
anti-EGFR inhibitors in TNBC treatments.27–29
Correlation between EGFR protein
expression and gene copy number alteration
Gene ampliﬁcation is an important mechanism for onco-
gene overexpression in malignant tumors and occurs
frequently in breast cancer.30 The EGFR gene ampliﬁca-
tion has been shown to result in increased protein expres-
sion in breast cancer.31 Immunohistochemical analysis has
suggested a strong association of EGFR, CK5/6 and c-KIT
protein expression with TNBC cases.32 Therefore, in this
study, we evaluated the EGFR protein expression levels
and gene copy number alteration and investigated the
correlation between these parameters in Malaysian
women population with TNBC.
The association between EGFR protein expression pat-
tern and EGFR gene copy number is listed in Table 2.
There was a positive correlation between EGFR protein
expression and gene copy number with P<0.015. EGFR
protein overexpression (IHC score of 2+ and 3+) was
observed in all (100%) of the samples with gene ampliﬁ-
cation. In seven cases with high polysomy, EGFR over-
expression was shown in four (57.2%) of the cases, while
the remaining two cases showed low immunoreactivity.
Ten (20.9%) of the 48 low copy number cases demon-
strated EGFR protein overexpression.
Discussion
The protein expression analysis by IHC coupled with gene
copy number evaluation by FISH is one of the most
effective methods in selecting patients for anti-EGFR ther-
apy. In our study, the EGFR copy number was evaluated
based on Capuzzo et al (2005) criteria which were derived
from the University of Colorado Cancer Center.26 In the
small Malaysian cohort used in this study, the EGFR gene
was ampliﬁed in 5.2% cases of the mixed (i.e., Malay,
Chinese, Indian, and foreign) race TNBC population. The
EGFR gene ampliﬁcation observed is low, but it is in
concordance with ampliﬁcation studies reported from the
Turkish and Korean population where the ampliﬁcation
rate was 1.62% and 2%, respectively.33–36 The EGFR
gene copy number (high polysomy and ampliﬁcation)
Table 2 Summary of FISH and IHC scores for the patient samples analyzed
FISH result Sample number Percentage IHC scoring Patient number Percentage
Disomy 6 10.3 0 26 44.83
Low trisomy 24 41.4 1+ 15 25.86
High trisomy 14 24.1 2+ 10 17.24
Low polysomy 5 8.62 3+ 7 12.07
High polysomy 6 10.3
Ampliﬁcation 3 5.17
Total: 58 100 Total: 58 100
Abbreviations: FISH, ﬂuorescence in situ hybridization; IHC, immunohistochemistry.
Zakaria et al Dovepress
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Figure 1 (A and B) Low gene copy number of EGFR gene (green:orange, 2:2 and 3:3), (C) high polysomy of EGFR gene (green:orange ≥4:4) and (D) EGFR gene ampliﬁcation
with orange cluster.
Table 3 Correlation of EGFR protein expression and copy number alterations
EGFR FISH analysis
Low gene copy numbera (%) High polysomy (%) Gene ampliﬁcation (%) Total
EGFR IHC
0 25 (51.0) 1 (16.7) 0 26
1+ 14 (28.6) 1 (16.7) 0 15
2+ 7 (14.3) 1 (16.7) 2 (66.7) 10
3+ 3 (6.1) 3 (50.0) 1 (33.3) 7
Total 49 6 3 58
Note: aLow copy number includes disomy, low trisomy, high trisomy and low polysomy.
Abbreviations: FISH, ﬂuorescence in situ hybridization; IHC, immunohistochemistry.
Table 4 Immunohistochemistry scoring
Score number Observation
0 No staining or weak membranous staining <10% of the tumour cells
1+ Weak membranous staining in ≥10% of the tumour cells
2+ Moderate, membranous staining in ≥10% of the tumour cells
3+ Strong membranous staining in ≥10% of the tumour cells
Dovepress Zakaria et al
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varies from 2.0% to 24.0% in other TNBC investigations
from Germany and Switzerland, respectively.20,34
Similar to the gene ampliﬁcation variation, EGFR muta-
tional analyses revealed no EGFR mutations in European
population but about 0% and 11% mutation frequency in
French and Chinese population, respectively.35 Further, in
the same vein, the correlation observed between gene ampli-
ﬁcation and protein expression in many studies also show
positive as well as negative correlations.20,36,37 Our results
from the Malaysian cohort show that EGFR protein overex-
pression was generally positively associated with high EGFR
gene copy number. Moreover, overexpression of EGFR is also
observed in 10 of the 48 TNBC patients who have low EGFR
gene copy number suggesting a signiﬁcant role for EGFR
mediated signaling in Malaysian TNBC cohort. The variabil-
ities observed in EGFR status in various TNBC cohorts could
be attributed to differences in TNBC biology, cellular behavior
of EGFR and the highly complex nature of oncogenesis, but it
is essential to note the diversity in criteria used for determining
cut-off EGFR copy number, techniques used for expression
detection, and methods of interpretations.38 For example, a
single centric Japanese study by Nakajima et al reported
EGFR gene ampliﬁcation and EGFR gene-activating muta-
tions not correlating to TNBC outcome indicating the complex
role of EGFR in TNBC development.38
In TNBC, the anti-EGFR antibodies, such as cetuxi-
mab or EGFR tyrosine kinase inhibitors (EGFR-TKI) like
geﬁtinib and erlotinib are used to suppress the EGFR
signaling pathway. The major breakthrough in EGFR-tar-
geted therapy against metastatic TNBC came from the
European Society of Medical Oncology which reported a
20% response in patients with metastatic TNBC receiving
Cetuximab in combination with Cisplatin opposed to
another patient cohort receiving Cisplatin alone where
the response rate was only 10%.39 The anti-EGFR anti-
body therapy in patients with TNBC who lack EGFR
mutations but display EGFR ampliﬁcation show beneﬁts
in few clinical trials.39,40 In our study, we found EGFR
protein overexpression in 29.3% of the TNBC cohort,
where only 15.5% showed high EGFR copy number.
Moreover, the clinical signiﬁcance of EGFR ampliﬁcation
and EGFR overexpression could not be evaluated in our
current study due to the small number of informative
cases. The EGFR status in large cohort of Malaysian
TNBC patient samples needs to be studied to check
whether EGFR-targeted therapy can be useful in
Malaysian TNBC patients. In conclusion, our study from
a small informative cohort shows EGFR overexpression
and positive correlation between high copy number and
protein expression in TNBC highlighting the need to per-
form a nationwide systematic EGFR status with clinical
outcome in Malaysian TNBC patients. This will enable us
to determine the possibility of using anti-EGFR combina-
torial therapy for this population.
Figure 2 Representation of stained cells based on the criteria shown in Table 4: (A) 0, (B) 1+, (C) 2+ and (D) 3+. The basis of scoring is given in detail in Table 4.
Zakaria et al Dovepress
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